Indication

Prevent extracorporeal clotting during hemodialysis

This clinical indication refers to the prevention of thrombosis within the artificial bloodlines and dialyzer membranes of an external dialysis circuit during renal replacement therapy. Read more about Prevent extracorporeal clotting during hemodialysis

45 drugs 23 manufacturers

Advertisement

Drugs that treat it

Common Prevent extracorporeal clotting during hemodialysis therapies.

Showing 19–27 of 45 drugs

Filter & compare in the drug finder →Opens the drug finder with Prevent extracorporeal clotting during hemodialysis preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Prevent extracorporeal clotting during hemodialysis.

This clinical indication refers to the prevention of thrombosis within the artificial bloodlines and dialyzer membranes of an external dialysis circuit during renal replacement therapy.

The target population comprises individuals with acute kidney injury or end-stage kidney disease undergoing intermittent or continuous hemodialysis.

Extracorporeal clotting is triggered when patient blood contacts synthetic, non-endothelial surfaces, combined with turbulence, air exposure, and shear stress, which activate the intrinsic coagulation cascade and stimulate platelet adhesion and aggregation.

Without appropriate prophylactic intervention, this state leads to premature circuit occlusion, diminished clearance of toxins and fluids, procedural interruption, and clinically significant blood loss.

Personalize your experience

Follow Prevent extracorporeal clotting during hemodialysis and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it